MedTrace Logo

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

NCT01687478 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2019-10-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.

Conditions

Interventions

DRUG

Olanzapine

Administered Orally

DRUG

Fluoxetine

Administered Orally

DRUG

Placebo

Administered Orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01687478 on ClinicalTrials.gov